Columbia Asset Management Has $901,000 Stake in Bristol-Myers Squibb Company (NYSE:BMY)

Columbia Asset Management raised its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,574 shares of the biopharmaceutical company’s stock after purchasing an additional 650 shares during the period. Columbia Asset Management’s holdings in Bristol-Myers Squibb were worth $901,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. American National Bank increased its stake in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 508 shares in the last quarter. Welch Investments LLC grew its stake in Bristol-Myers Squibb by 3.9% during the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 79 shares in the last quarter. Crestwood Advisors Group LLC purchased a new position in Bristol-Myers Squibb during the first quarter valued at approximately $116,000. Blue Chip Partners Inc. grew its stake in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its stake in Bristol-Myers Squibb by 2.8% during the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 68.80% of the company’s stock.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Company (BMY) traded up 0.24% during trading on Friday, hitting $62.84. 3,730,072 shares of the stock traded hands. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $63.47. The stock has a 50 day moving average of $58.32 and a 200 day moving average of $55.91. The firm has a market cap of $103.05 billion, a price-to-earnings ratio of 22.95 and a beta of 1.18. Bristol-Myers Squibb also was the recipient of unusually large options trading on Thursday. Stock traders purchased 781 put options on the company. This represents an increase of approximately 117% compared to the average volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.69 EPS. Analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.49%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.

WARNING: This article was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://baseballnewssource.com/markets/columbia-asset-management-acquires-650-shares-of-bristol-myers-squibb-company-bmy/1604190.html.

BMY has been the subject of several recent analyst reports. Jefferies Group LLC boosted their price objective on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Monday. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price for the company in a research report on Wednesday, July 12th. Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price for the company. in a research report on Tuesday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Finally, BMO Capital Markets restated an “underperform” rating and issued a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $62.66.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.